3199-50-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-BROMO-2-FURYL)ETHANONE is used as a synthetic intermediate for the production of various pharmaceuticals, leveraging its reactivity and structural features to create a range of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(5-BROMO-2-FURYL)ETHANONE is utilized as a precursor in the synthesis of agrochemicals, contributing to the development of effective pest control agents and other agricultural products.
Used in Flavor and Fragrance Industry:
1-(5-BROMO-2-FURYL)ETHANONE is employed as a reagent in the preparation of flavoring agents and perfumes, capitalizing on its distinctive odor to enhance or create unique scents for various applications.
Used in Material Science:
1-(5-BROMO-2-FURYL)ETHANONE is also used in the development of new materials, where its unique chemical structure allows for the creation of innovative and improved materials with specific properties.
Used in Bioactive Molecule Development:
1-(5-BROMO-2-FURYL)ETHANONE is utilized in the synthesis of bioactive molecules, potentially leading to the discovery of new therapeutic agents or other biologically relevant compounds.

Upstream product

• 186581-53-3 diazomethane 
• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 6132-37-2 ethyl 5-bromofuran-2-carboxylate 
• 141-78-6 ethyl acetate 
• 3199-47-1 (5-bromo-[2]furyl)-propiolic acid 
• 83256-79-5 (2RS,3SR)-2,3-dibromo-3-(5-bromo-[2]furyl)-propionic acid ethyl ester 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 69536-36-3 2-(furan-2-yl)-2-methyl-[1,3]dioxolane 
• 7732-18-5 water 
• 1192-62-7 1-(2-furyl)-1-ethanone 
• 75-16-1 methylmagnesium bromide 
• 179055-22-2 N-methyl-N-methoxy-5-bromofuran-2-carboxamide 
• 585-70-6 5-bromo-furan-2-carboxylic acid 

Downstream Products

• 17357-32-3 2-bromo-1-(5-bromofuran-2-yl)ethanone 
• 99834-89-6 [4-(5-Acetyl-furan-2-yloxy)-phenyl]-acetic acid methyl ester 
• 99834-91-0 2-[4-(5-Acetyl-furan-2-yloxy)-phenyl]-propionic acid methyl ester 
• 99834-93-2 2-[4-(5-Acetyl-furan-2-yloxy)-phenyl]-butyric acid methyl ester 
• 1202918-49-7 3-(5-acetylfuran-2-yl)benzoic acid methyl ester 
• 53355-32-1 methyl 4-(5-acetylfuran-2-yl)benzoate 
• 1245794-44-8 1-methyl-2-phenyl-5-(5'-bromo-2'-furyl)imidazole 
• 1202918-50-0 3-(5-acetylfuran-2-yl)benzoic acid 
• 1202918-51-1 1-{5-[3-(4-methyl[1,4]diazepane-1-carbonyl)phenyl]furan-2-yl}ethanone 
• 1353859-02-5 5-chloro-3-(1-(5-(3-(4-methyl-1,4-diazepane-1-carbonyl)phenyl)furan-2-yl)ethylidene)indolin-2-one 
• 62642-12-0 2‐acetyl‐5‐phenylfuran 

Relevant academic research and scientific papers

Discovery of boronic acid-based fluorescent probes targeting amyloid-beta plaques in Alzheimer's disease

A boronic acid-based fluorescent probe was developed for diagnosis of amyloid-β (Aβ) plaques from Alzheimer's disease (AD). Probe 4c, which included boronic acid as a functional group, exhibited a significant increase (64.37-fold, FAβ/F0) in fluorescence intensity as a response to Aβ aggregates, with a blue shift (105?nm) in the maximum emission wavelength. We found that boronic acid as a functional group improved the binding affinity (KDvalue?=?0.79?±?0.05?μM for 4c) for Aβ aggregates and confirmed that 4c selectively stained Aβ plaques in brain sections from APP/PS1 mice. Ex vivo fluorescence imaging using mice (normal and APP/PS1) also revealed that 4c was able to penetrate the blood–brain barrier (BBB) and to stain Aβ plaques in the brain. From these results, we believe that 4c will be useful as a fluorescent probe in preclinical research related to AD. Furthermore, we believe that our results with boronic acid also provide valuable information for the development of a probe for Aβ plaques.

Gram-Scale, Stereoselective Synthesis and Biological Evaluation of (+)-Armillariol C

Natural products with heteroaromatic cores are ample and widespread in nature, with many compounds exhibiting promising therapeutic properties. (+)-Armillariol C (1a) is a furan-based natural product isolated from Armillaria species. Herein, we report the first enantioselective synthesis of (+)-armillariol C (1a, 79% overall yield), its enantiomer (1b), and four other analogues, on a gram-scale, using microwave-mediated, Suzuki-Miyaura cross-coupling and Sharpless asymmetric dihydroxylation reactions. Compounds were tested for plant- and mycelia-growth regulatory activity, with 1b, 7a, and 7b showing the strongest inhibitory properties in a lettuce assay and 7b and 9b inhibiting Flammulina velutipes.

Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action

Increased protein synthesis is a requirement for malignant growth, and as a result, translation has become a pharmaceutical target for cancer. The initiation of cap-dependent translation is enzymatically driven by the eukaryotic initiation factor (eIF)4A, an ATP-powered DEAD-box RNA-helicase that unwinds the messenger RNA secondary structure upstream of the start codon, enabling translation of downstream genes. A screen for inhibitors of eIF4A ATPase activity produced an intriguing hit that, surprisingly, was not ATP-competitive. A medicinal chemistry campaign produced the novel eIF4A inhibitor 28, which decreased BJAB Burkitt lymphoma cell viability. Biochemical and cellular studies, molecular docking, and functional assays uncovered that 28 is an RNA-competitive, ATP-uncompetitive inhibitor that engages a novel pocket in the RNA groove of eIF4A and inhibits unwinding activity by interfering with proper RNA binding and suppressing ATP hydrolysis. Inhibition of eIF4A through this unique mechanism may offer new strategies for targeting this promising intersection point of many oncogenic pathways.

NEUTRON CAPTURE THERAPY SYSTEM FOR ELIMINATING AMYLOID Beta-PROTEIN DEPOSITION PLAQUE

The present disclosure provides a neutron capture therapy system for eliminating amyloid β-protein deposition plaque, comprising a neutron capture therapy device and a 10B-containing compound capable of specifically binding to amyloid β-protein

Visible-Light-Mediated Radical Arylation of Anilines with Acceptor-Substituted (Hetero)aryl Halides

A visible-light-mediated, catalyst-free, direct (hetero)arylation of anilines with mild reaction conditions has been developed. The formation of a donor-acceptor complex between electron-withdrawing substituted (hetero)aryl halides and anilines allows, under blue LED irradiation, the synthesis of ortho and para (hetero)arylated anilines in moderate to good yields. The reaction has a high functional group tolerance. Spectroscopic studies confirmed the donor-acceptor complex formation between aniline and aryl halide.

LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containg such compounds.

Discovery of CX-6258. A potent, selective, and orally efficacious pan-pim kinases inhibitor

Structure-activity relationship analysis in a series of 3-(5-((2-oxoindolin-3-ylidene)methyl)furan-2-yl)amides identified compound 13, a pan-Pim kinases inhibitor with excellent biochemical potency and kinase selectivity. Compound 13 exhibited in vitro synergy with chemotherapeutics and robust in vivo efficacy in two Pim kinases driven tumor models.

COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE

There is provided a composition comprising a compound represented by general formula (I), wherein Rl represents a 5-iodothiophen-2-yl group or the like, and R2 represents a 4-dimethylaminophenyl group or the like. This composition is useful for diagnosis of an amyloid-related disease such as Alzheimer's disease because the compound has high binding specificity to amyloid β protein, high permeability through the blood-brain barrier, and a property of being rapidly eliminated from sites other than senile plaques in the brain.

DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE

The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health.

COMPOSITION FOR DIAGNOSING AMYLOID-RELATED DISEASE

There is provided a composition comprising a compound represented by general formula (I), wherein R1 represents a 5-iodothiophen-2-yl group or the like, and R2 represents a 4-dimethylaminophenyl group or the like. This composition is useful for diagnosis of an amyloid-related disease such as Alzheimer's disease because the compound has high binding specificity to amyloid β protein, high permeability through the blood-brain barrier, and a property of being rapidly eliminated from sites other than senile plaques in the brain.